A network for students interested in evidence-based health care

Time to change how we treat deep vein thrombosis

Posted on July 16, 2015 by Pishoy Gouda

Evidence Reviews
DVT

What is a DVT?

Deep vein thrombosis (DVT) is a medical condition that results in a clot forming in your veins. Most commonly these clots develop in the veins of leg, but can actually form in any vein in the body. Rudolf Virchow, a German physician from the 1800’s, came up with three categories of why people may develop clots. These are hypercoagulability (sticky blood), hemodynamic changes (blood not moving) and endothelial injury (damage to the blood vessel walls). In real life, these might occur after someone undergoes surgery, during pregnancy or on a long haul flight. However, sometimes there is no reason at all! When these clots develop, they cause the leg to swell and to become very painful. However, one of the real dangers is if the clot gets released and travels into the lungs, where it can cause serious problem by preventing blood from reaching the alveoli, which is called a pulmonary embolism (PE).

How we used to treat it

Up until recently DVTs were treated with a combination of unfractionated heparin (UFH) or a low molecular weight heparin (LMWH) and a vitamin K antagonist, usually Warfarin/Coumadin. Both heparins work by targeting an enzyme inhibitor, antithrombin III. When the heparin is bound to antithrombin III, it pretty much gives it super powers, deactivating clotting factors at 1000 times the normal speed. The end result, it becomes a lot harder for clots to form. Warfarin takes a little bit longer to work, as it targets vitamin K. Vitamin K is required in the formation of several clotting factors. Warfarin works, by binding a vitamin K epoxide reductase, which diminishes the levels of vitamin K that can actually be used.

The new kids on the block

Two further types of anticoagulants have been developed in recent years that have been coined Novel Oral Anticoagulants, or NOACs for short. These include oral direct thrombin inhibitors and Factor Xa inhibitors. The thrombin inhibitors work simply by inhibiting thrombin, stopping the clotting cascade. While the factor Xa inhibitors target that one specific clotting factor that is essential in the clotting cascade.

Should we switch to NOACs?

Up until recently, the answer really depended on which study you read. Recently, Robertson et al. from the Cochrane published a systematic review on the use of oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. This is the first systematic review to look at DVTs specifically, and not both DVTs and PEs together. Here is what they found!

  • They included 11 studies that included over 27 945 participantsDVT table 1
    • 3 of these compared oral DTIs with the standard LMWH + Warfarin
    • 8 of these compared oral factor Xa inhibitors with the standard
  • The excluded 6 studies because:
    • They were not randomized controlled trials
    • Included participants in other trials
    • Too short (4 weeks)
    • The control group was given a placebo rather than the standard therapy

Summary of results

DVT table 2

What this all means

This new systematic review and meta-analysis makes it pretty clear, that although these new NOACs may not prevent new clots better than the standard therapy, they do reduce the risk of major bleeding associated with LMWH + warfarin. However, NOACs have other advantages such as being able to be administered orally, rather than a subcutaneously for heparin. There is no need for continual monitoring or dose changes, such as with warfarin. However, we need to be careful using NOACs in patients with renal disease, as many of these drugs are renally excreted.

Further research

It would be great to see future studies that directly compare DTI vs Xa inhibitors, or even studies that compare different drugs from the same class. Future sub study analysis would also be beneficial to see if NOACs are of more value in certain situations such as malignancy induced clotting. Finally, it is going to be pretty interesting to see real life data of the use of these NOACs when their antidotes hit the market, which are currently in clinical trials. These drugs have shown that they have potential to displace the current standard treatment for DVTs and clinical practice is slowly moving in that direction.

Creative Commons License
Time to Change How We Treat Deep Vein Thrombosis by Pishoy Gouda is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Based on a work at http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010956.pub2/abstract. All images used within the blog are not available for reuse or republication as they are purchased for Students 4 Best Evidence from shutterstock.com.

Tags:

Pishoy Gouda

Pishoy is a medical graduate from the National University of Ireland, Galway (NUI Galway). He was the founding Chairperson of the Association of Medical Students in Ireland and now currently serves on their advisory panel. He is currently a PGY 1 Internal Medicine Resident and the University of Calgary and completing his MSc in Clinical Trials at the London School of Hygiene and Tropical Medicine. View more posts from Pishoy

Leave a Reply

Your email address will not be published. Required fields are marked *

One Comment on Time to change how we treat deep vein thrombosis

  • John Von

    This treatment should be more to be used,well written great study,tnx for sharing!

    November 20, 2017 at 12:16 pm
    Reply to John

Subscribe to our newsletter

You will receive our monthly newsletter and free access to Trip Premium.